Evidence map›Paper›PMID 34257550›Full record

ArticlePathology oncology research : POR2021

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.

Roberto Chalela, Jose Gregorio González-García, Karys Khilzi, Víctor Curull, Albert Sánchez-Font, Raquel Longarón, María Teresa Rodrigo-Calvo, Clara Martín-Ontiyuelo, Joaquim Gea, Beatríz Bellosillo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Roberto ChalelaHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Jose Gregorio González-GarcíaHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Karys KhilziRespiratory Medicine Department, Hospital del Mar PSMAR, Barcelona, Spain.
Víctor CurullHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Albert Sánchez-FontHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Raquel LongarónPathology Department, Hospital del Mar PSMAR, Barcelona, Spain.
María Teresa Rodrigo-CalvoPathology Department, Hospital del Mar PSMAR, Barcelona, Spain.
Clara Martín-OntiyueloHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Joaquim GeaHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Beatríz BellosilloHospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Hospital del Mar Research Institute · ESUniversitat Autònoma de Barcelona · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESPompeu Fabra University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically "healthy cells".

Indexed as

MutationAdenocarcinoma of LungAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesErbB ReceptorsFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedParenchymal TissuePrognosisProto-Oncogene Proteins p21(ras)Biomarkers, TumorEGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)adenocacinoma lungdriver mutationEGFR–epidermal growth factor receptorKRASPrognosis

Identifiers

PMID34257550
PMCPMC8262165
OpenAlexW3139323586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.